Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Rao, J S ^a   Keleshian, V L ^a   Klein, S ^a   Rapoport, S I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer's disease; arachidonic acid cascade; bipolar disorder; DNA methylation; drebrin; synaptophysin

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; CYTOCHROME P450; DREBRIN; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SYNAPTOPHYSIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BIPOLAR DISORDER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FRONTAL CORTEX; HISTONE ACETYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MENTAL PATIENT; PROMOTER REGION;

AGED; ALZHEIMER DISEASE; ARACHIDONIC ACID; BIPOLAR DISORDER; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; FRONTAL LOBE; HISTONES; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC;

EID: 84863757162     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.55     Document Type: Article

References (67)

1. Kim HW, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry 2011; 16: 419-428.
2. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15: 384-392.
3. Rao JS, Rapoport S, Kim H-W. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer's disease brain. Transl Psychiatry 2011; 1: 1-9.
4. Frisoni GB, Rozzini L, Gozzetti A, Binetti G, Zanetti O, Bianchetti A et al. Behavioral syndromes in Alzheimer's disease: description and correlates. Dement Geriatr Cogn Disord 1999; 10: 130-138. (Pubitemid 29099697)
5. Kalmar JH, Wang F, Spencer L, Edmiston E, Lacadie CM, Martin A et al. Preliminary evidence for progressive prefrontal abnormalities in adolescents and young adults with bipolar disorder. J Int Neuropsychol Soc 2009; 15: 476-481.
6. Lisy ME, Jarvis KB, DelBello MP, Mills NP, Weber WA, Fleck D et al. Progressive neurostructural changes in adolescent and adult patients with bipolar disorder. Bipolar disorders 2011; 13: 396-405.
7. Hellvin T, Sundet K, Simonsen C, Aminoff SR, Lagerberg TV, Andreassen OA et al. Neurocognitive functioning in patients recently diagnosed with bipolar disorder. Bipolar disorders 2012; 14: 227-238.
8. Baum AE, Hamshere M, Green E, Cichon S, Rietschel M, Noethen MM et al. Meta-analysis of two genome-wide association studies of bipolar disorder reveals important points of agreement. Mol Psychiatry 2008; 13: 466-467. (Pubitemid 351556036)
9. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753.
10. Burns LC, Minster RL, Demirci FY, Barmada MM, Ganguli M, Lopez OL et al. Replication study of genome-wide associated SNPs with late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 507-512.
11. Craddock N, Owen MJ, O'Donovan MC. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol Psychiatry 2006; 11: 446-458.
12. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 2005; 5: 149-160. (Pubitemid 40994274)
13. Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2003; 4: 597-621. (Pubitemid 37120947)
14. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266. (Pubitemid 37328861)
15. Gräff J, Kim D, Dobbin MM, Tsai L-H. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol Rev 2011; 91: 603-649.
16. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007; pp: 635-638. (Pubitemid 46273578)
17. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet 2000; 1: 11-19.
18. Feng J, Zhou Y, Campbell SL, Le T, Li E, Sweatt JD et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci 2010; 13: 423-430.
19. Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY et al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996; 84: 843-851. (Pubitemid 26106854)
20. Loury R, Sassone-Corsi P. Histone phosphorylation: how to proceed. Methods 2003; 31: 40-48. (Pubitemid 36945169)
21. Shiio Y, Eisenman RN. Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci USA 2003; 100: 13225-13230. (Pubitemid 37444723)
22. Fukuda H, Sano N, Muto S, Horikoshi M. Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genomic Proteomic 2006; 5: 190-208. (Pubitemid 46470220)
23. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 2006; 75: 243-269. (Pubitemid 44118033)
24. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128: 707-719. (Pubitemid 46273570)
25. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355-367. (Pubitemid 46652469)
26. Rao JS, Rapoport SI, Kim HW. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer's disease brain. Transl Psychiatry 2011; 1: e31.
27. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 2010; 37: 596-603.
28. Chen KH, Reese EA, Kim HW, Rapoport SI, Rao JS. Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheimers Dis 2011; 26: 755-766.
29. Aoki C, Kojima N, Sabaliauskas N, Shah L, Ahmed TH, Oakford J et al. Drebrin a knockout eliminates the rapid form of homeostatic synaptic plasticity at excitatory synapses of intact adult cerebral cortex. J Comp Neurol 2009; 517: 105-121.
30. Aisa B, Gil-Bea FJ, Solas M, Garcia-Alloza M, Chen CP, Lai MK et al. Altered NCAM expression associated with the cholinergic system in Alzheimer's disease. J Alzheimer's Dis 2010; 20: 659-668.
31. Armstrong RA. Is the clustering of beta-amyloid (A beta) deposits in the frontal cortex of Alzheimer patients determined by blood vessels? Neurosci Lett 1995; 195: 121-124.
32. Armstrong RA, Cairns NJ, Lantos PL. Spatial distribution of diffuse, primitive, and classic amyloid-beta deposits and blood vessels in the upper laminae of the frontal cortex in Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 378-383. (Pubitemid 29050755)
33. Fischer B, Popa-Wagner A. [Alzheimer disease: involvement of the complement system in cell death. Gene expression of C1q and C3 in the frontal cortex of patients with Alzheimer disease and control probands]. Fortschritte der Medizin 1996; 114: 161-163.
34. Nordberg A, Winblad B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 1986; 72: 115-119. (Pubitemid 17184928)
35. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljarvi L, Talasniemi S et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett 1995; 187: 79-82.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
37. Lopez-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry 2002; 52: 93-100. (Pubitemid 34756554)
38. Lyoo IK, Kim MJ, Stoll AL, Demopulos CM, Parow AM, Dager SR et al. Frontal lobe gray matter density decreases in bipolar I disorder. Biol Psychiatry 2004; 55: 648-651. (Pubitemid 38315040)
39. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002; 4: 105-116. (Pubitemid 34411273)
40. Buchsbaum MS, Wu J, DeLisi LE, Holcomb H, Kessler R, Johnson J et al. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F] 2-deoxyglucose in affective illness. J Affect Disord 1986; 10: 137-152. (Pubitemid 16067656)
41. Rubinsztein JS, Fletcher PC, Rogers RD, Ho LW, Aigbirhio FI, Paykel ES et al. Decision-making in mania: a PET study. Brain 2001; 124: 2550-2563. (Pubitemid 33134942)
42. Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 1992; 106: 14-18.
43. Rao JS, Klein S, VL K, Reese EA, Rapoport SI. Epigenetic modifications in postmortem frontal cortex from bipolar disorder and Alzheimer's disease patients. 50th Annual Meeting of American College of Neuropsychopharmacology; 05 December 2011; Hawaii, USA; 2011, p. 226.
44. Bazinet RP, Rao JS, Chang L, Rapoport SI, Lee HJ. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry 2006; 59: 401-407. (Pubitemid 43289218)
45. Haeckel A, Ahuja R, Gundelfinger ED, Qualmann B, Kessels MM. The actin-binding protein Abp1 controls dendritic spine morphology and is important for spine head and synapse formation. J Neurosci 2008; 28: 10031-10044.
46. Morri H, Ozaki M, Watanabe Y. 50-flanking region surrounding a human cytosolic phospholipase A2 gene. Biochem Biophys Res Commun 1994; 205: 6-11.
47. Antonio V, Brouillet A, Janvier B, Monne C, Bereziat G, Andreani M et al. Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors. Biochem J 2002; 368: 415-424. (Pubitemid 35454520)
48. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002; 68-69: 95-114. (Pubitemid 35247390)
49. Pereira SG, Oakley F. Nuclear factor-kappaB1: regulation and function. Int J Biochem Cell Biol 2008; 40: 1425-1430.
50. Niederberger E, Schmidtko A, Gao W, Kuhlein H, Ehnert C, Geisslinger G. Impaired acute and inflammatory nociception in mice lacking the p50 subunit of NF-kappaB. Eur J Pharmacol 2007; 559: 55-60. (Pubitemid 46274646)
51. Rao JS, Ertley RN, Rapoport SI, Bazinet RP, Lee HJ. Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. J Neurochem 2007; 102: 1918-1927. (Pubitemid 47329252)
52. Li W, Xia J, Sun GY. Cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC): response to genistein and pyrrolidine dithiocarbamate. J Interferon Cytokine Res 1999; 19: 121-127. (Pubitemid 29109628)
53. Chang Y, Kim H-W, Rapoport S, Rao J. Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation. Neurochem Res 2008; 33: 2318-2323.
54. Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996; 55: 1023-1025. (Pubitemid 26338013)
55. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007; 68: 1501-1508. (Pubitemid 46685921)
56. Maezawa I, Nivison M, Montine KS, Maeda N, Montine TJ. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J 2006; 20: 797-799. (Pubitemid 46671219)
57. Bellizzi D, D'Aquila P, Montesanto A, Corsonello A, Mari V, Mazzei B et al. Global DNA methylation in old subjects is correlated with frailty. Age 2012; 34: 169-179.
58. Cadieux B, Ching TT, VandenBerg SR, Costello JF. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylene-tetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 2006; 66: 8469-8476. (Pubitemid 44449159)
59. Tikoo K, Lau SS, Monks TJ. Histone H3 phosphorylation is coupled to poly-(ADP-ribosylation) during reactive oxygen species-induced cell death in renal proximal tubular epithelial cells. Mol Pharmacol 2001; 60: 394-402. (Pubitemid 32678306)
60. Rapoport SI, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 2009; 61: 185-209.
61. Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol 2009; 2: 207-214.
62. Rao JS, Bazinet RP, Rapoport SI, Lee HJ. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord 2007; 9: 513-520. (Pubitemid 47202514)
63. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-2826. (Pubitemid 37430117)
64. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30: 1204-1215. (Pubitemid 40720980)
65. Chang YC, Rapoport SI, Rao JS. Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem Res 2009; 34: 536-541.
66. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004; 16: 83-90.
67. Keilhoff G, Grecksch G, Bernstein HG, Roskoden T, Becker A. Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psychiatry Clin Neurosci 2010; 260: 151-162.